Table 1 Ongoing clinical trial of oncolytic adenovirus. The virus name and fiber modifications employed for enhancing internalization of various oncolytic adenovirus are presented
From: Overcoming the limitations of locally administered oncolytic virotherapy
Trial ID | Phase | Disease Condition | Oncolytic adenovirus | Fiber modification | Internalization mechanism | Administration Route | Monotherapy/Combination therapy |
|---|---|---|---|---|---|---|---|
NCT03029871 | I | Lung cancer | Ad5-yCD/mutTKSR39rep-ADP | None | Coxsackie and adenovirus receptor (CAR) | Local delivery | Combination therapy |
NCT02555397 | I | Prostate cancer | Ad5-yCD/mutTKSR39rep-hIL12 | None | CAR | Local delivery | Monotherapy |
NCT03281382 | I | Pancreatic cancer | Ad5-yCD/mutTKSR39rep-hIL12 | None | CAR | Local delivery | Combination therapy |
NCT03190824 | II | Skin cancer | OBP-301 | None | CAR | Local delivery | Monotherapy |
NCT02045602 | I | Multiple cancer types | VCN-01 | replacement of the heparan sulfate glycosaminoglycan putative-binding site KKTK of the fiber shaft with an integrin-binding motif RGDK for tumor targeting | Integrin | Systemic delivery | Combination therapy |
NCT03799744 | I | Head and neck cancer | VCN-01 | replacement of the heparan sulfate glycosaminoglycan putative-binding site KKTK of the fiber shaft with an integrin-binding motif RGDK for tumor targeting | Integrin | Systemic delivery | Combination therapy |
NCT03225989 | I/II | Multiple cancer types | LOAd703 | Serotype 35 adenovirus fiber | CD46 | Local delivery | Combination therapy |
NCT02705196 | I/II | Pancreatic cancer | LOAd703 | Serotype 35 adenovirus fiber | CD46 | Local delivery | Combination therapy |
NCT03003676 | I | Skin cancer | ONCOS-102 | serotype 5/3 capsid-modified adenovirus | Desmoglein 2 | Local delivery | Combination therapy |
NCT03514836 | I/II | Prostate cancer | ONCOS-102 | serotype 5/3 capsid-modified adenovirus | Desmoglein 2 | Local delivery | Combination therapy |
NCT02879669 | I/II | Pleural mesothelioma | ONCOS-102 | serotype 5/3 capsid-modified adenovirus | Desmoglein 2 | Local delivery | Combination therapy |
NCT03852511 | I | Multiple cancer types | NG-350A | group B Ad11p/Ad3 chimeric adenovirus | Desmoglein 2 | Local & Systemic delivery | Monotherapy |
NCT03714334 | I | Brain cancer | DNX-2440 | insertion of integrin binding RGD-4C motif for tumor targeting in fiber domain | Integrin | Local delivery | Monotherapy |
NCT03178032 | I | Brain cancer | DNX-2401 | insertion of integrin binding RGD-4C motif for tumor targeting in fiber domain | Integrin | Local delivery | Monotherapy |
NCT02798406 | II | Brain cancer | DNX-2401 | insertion of integrin binding RGD-4C motif for tumor targeting in fiber domain | Integrin | Local delivery | Combination therapy |
NCT03896568 | I | Brain cancer | BM-Ad5-DNX-2401(DNX-2401 loaded into mesenchymal stem cell) | insertion of integrin binding RGD-4C motif for tumor targeting in fiber domain | Integrin | Systemic delivery | Combination therapy |
NCT03072134 | I | Brain cancer | NSC-CRAd-Survivin-pk7(Neural stem cells loaded with CRAd-Survivin-pk7) | fiber protein polylysine modification (pk7) for enhanced cell internalization | Nonspecific enhancement in cell uptake through increased cationic charge (polylysine) | Local delivery | Combination therapy |